SUVEN PHARMACEUTICALS
|
SUVEN PHARMACEUTICALS Last 5 Year Financial Ratios History
[Consolidated]
| Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 16.16 | 17.83 | 14.23 | 24.91 | - |
| CEPS(Rs) | 18.03 | 19.36 | 13.37 | 11.48 | - |
| DPS(Rs) | 6.00 | 5.00 | 2.00 | 5.00 | - |
| Book NAV/Share(Rs) | 68.16 | 59.99 | 46.39 | 66.37 | - |
| Tax Rate(%) | 26.52 | 32.02 | 25.45 | 24.56 | 30.78 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 42.78 | 44.03 | 43.87 | 46.15 | 45.40 |
| EBIT Margin(%) | 42.68 | 51.18 | 42.15 | 45.50 | 42.52 |
| Pre Tax Margin(%) | 41.72 | 50.53 | 41.00 | 42.73 | 41.78 |
| PAT Margin (%) | 30.66 | 34.35 | 30.56 | 32.24 | 28.92 |
| Cash Profit Margin (%) | 34.22 | 37.31 | 33.70 | 35.06 | 31.96 |
| Performance Ratios | |||||
| ROA(%) | 20.18 | 25.62 | 21.52 | 25.50 | 13.39 |
| ROE(%) | 25.21 | 33.52 | 30.47 | 37.80 | 18.92 |
| ROCE(%) | 33.41 | 45.92 | 36.19 | 44.55 | 23.87 |
| Asset Turnover(x) | 0.66 | 0.75 | 0.70 | 0.79 | 0.46 |
| Sales/Fixed Asset(x) | 1.71 | 2.09 | 1.97 | 2.07 | 1.09 |
| Working Capital/Sales(x) | 1.57 | 1.44 | 2.93 | 4.36 | 1.63 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.59 | 0.48 | 0.51 | 0.48 | 0.92 |
| Receivable days | 47.25 | 46.80 | 39.69 | 57.94 | 142.49 |
| Inventory Days | 81.11 | 66.93 | 67.95 | 72.66 | 151.76 |
| Payable days | 77.47 | 87.45 | 94.44 | 100.95 | 192.73 |
| Valuation Parameters | |||||
| PER(x) | 29.26 | 34.66 | 34.80 | 4.04 | - |
| PCE(x) | 26.22 | 31.91 | 37.07 | 8.77 | - |
| Price/Book(x) | 6.93 | 10.30 | 10.68 | 3.04 | - |
| Yield(%) | 1.27 | 0.81 | 0.40 | 2.48 | - |
| EV/Net Sales(x) | 8.98 | 11.95 | 12.62 | 3.28 | - |
| EV/Core EBITDA(x) | 19.40 | 23.41 | 27.87 | 6.79 | - |
| EV/EBIT(x) | 21.02 | 23.34 | 29.94 | 7.21 | - |
| EV/CE(x) | 5.70 | 8.02 | 8.08 | 2.12 | - |
| M Cap / Sales | 8.98 | 11.92 | 12.49 | 3.08 | - |
| Growth Ratio | |||||
| Net Sales Growth(%) | 1.52 | 30.75 | 21.10 | 120.68 | - |
| Core EBITDA Growth(%) | -7.99 | 47.43 | 13.49 | 134.02 | - |
| EBIT Growth(%) | -15.32 | 58.86 | 12.19 | 136.13 | - |
| PAT Growth(%) | -9.37 | 47.05 | 14.81 | 145.98 | - |
| EPS Growth(%) | -9.37 | 25.24 | -42.85 | - | - |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.04 | 0.06 | 0.12 | 0.22 | 0.14 |
| Current Ratio(x) | 3.81 | 3.64 | 2.07 | 1.60 | 2.22 |
| Quick Ratio(x) | 2.78 | 2.82 | 1.45 | 1.05 | 1.39 |
| Interest Cover(x) | 44.69 | 79.29 | 36.48 | 16.45 | 57.60 |
| Total Debt/Mcap(x) | 0.01 | 0.01 | 0.01 | 0.07 | - |
Compare Financial Ratios of peers of SUVEN PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| SUVEN PHARMACEUTICALS | ₹16,417.9 Cr | 0.4% | 2.4% | 34.9% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹364,831.0 Cr | -0.1% | -2.8% | 50.3% | Stock Analytics | |
| CIPLA | ₹113,471.0 Cr | 4.5% | -3.1% | 52.8% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹103,713.0 Cr | 4.6% | 1.4% | 22.2% | Stock Analytics | |
| DIVIS LABORATORIES | ₹101,960.0 Cr | 4.7% | 10.8% | 18.1% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹95,687.8 Cr | 3.1% | -4.1% | 80.4% | Stock Analytics | |
SUVEN PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SUVEN PHARMACEUTICALS | 0.4% |
2.4% |
34.9% |
| SENSEX | 1.3% |
2.6% |
24% |
You may also like the below Video Courses
